Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Buy” by Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given a consensus rating of “Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $57.50.

COLL has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Finally, Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th.

Collegium Pharmaceutical Price Performance

Shares of COLL remained flat at $37.03 during trading hours on Friday. The company had a trading volume of 480,480 shares, compared to its average volume of 425,763. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The company has a market cap of $1.20 billion, a PE ratio of 18.15 and a beta of 0.73. Collegium Pharmaceutical has a fifty-two week low of $29.19 and a fifty-two week high of $50.79. The company’s fifty day moving average price is $34.36 and its two-hundred day moving average price is $39.26.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.49 EPS. Research analysts predict that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in COLL. Group One Trading LLC purchased a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $28,000. Caitong International Asset Management Co. Ltd grew its holdings in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the period. PNC Financial Services Group Inc. grew its holdings in Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the period. Kemnay Advisory Services Inc. acquired a new position in Collegium Pharmaceutical during the fourth quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 318 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.